Skip to main content

ARC-12 A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination with AB122 in Participants with Advanced Malignancies

NCT04772989

A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination with AB122 in Participants with Advanced Malignancies

Associated Conditions

Malignant Pleural Mesothelioma

Principal Investigator

Sponsor

Arcus Biosciences, Inc

The purpose of the study is to help the Sponsor understand whether study drugs, AB308 together with zimberelimab (also called AB122) can be safely given to patients with the type of cancer you have. These study drugs are investigational because they are not approved by the United States Food and Drug Administration (US FDA), or any other agencies like the US-FDA, to treat the type of cancer you have

This study is currently enrolling.